RxDoctor Payments Data

Ann Linnebur, MD

Cardiovascular Disease · Los Alamos, NMNPI 1043273543

Payments from drug & device makers

$596in general payments, 2019–2025

Across 13 payments — averaging $45.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$135
  • Johnson & Johnson$133
  • Eko Health, Inc.$117
  • AstraZeneca$59
  • Hitachi Healthcare Americas Corp.$45
  • Covidien LP$45
  • plus $64 from 3 others

What the payments were for

  • Travel & lodging$468%
  • Food & beverage$50685%
  • Entertainment$458%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences5$135
Johnson & Johnson1$133
Eko Health, Inc.1$117
AstraZeneca1$59
Hitachi Healthcare Americas Corp.1$45
Covidien LP1$45
Philips North America LLC1$35
AbbVie1$14
Pfizer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$596 in reported general payments places this provider in the 30th percentile of 101 cardiovascular disease providers in New Mexico.

See all cardiovascular disease providers in New Mexico

Medicare billing

Part B allowed, 2024
$321,040
Medicare patients
836
Services billed
3,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban107$106,599
EliquisApixaban103$97,438
EntrestoSacubitril/Valsartan60$50,734
Repatha SureclickEvolocumab22$11,402
Eplerenone63$4,182
Estradiol19$2,320
Fentanyl12$2,216
SymbicortBudesonide/Formoterol Fumarate11$2,197
Atorvastatin Calcium150$2,060
Flecainide Acetate65$1,904
Levothyroxine Sodium143$1,783
Potassium Chloride58$1,570
Metoprolol Succinate40$1,069
Gabapentin33$1,061
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen38$1,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$133$106,599107 claims
PfizerEliquis$14$97,438103 claims
AstraZenecaSymbicort$59$2,19711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 101 cardiovascular disease providers in New Mexico.

Other cardiovascular disease in Los Alamos

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →